** Shares of Maryland-based vaccine maker Novavax NVAX.O fall 2.8% to $7.96
** Co says it received a notice on March 7 terminating with immediate effect a purchase agreement with Canada due to missed regulatory approval deadlines for its COVID-19 vaccine
** Co entered into the purchase agreement with Canada in January 2021
** Under the terms of the agreement, $28 million in advanced purchase payments previously received by the company are now refundable to the customer within 30 days of notice
** Up to last close, NVAX had risen 50.% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。